Disease landscape

Glioma clinical trials

Get alerts when Glioma trials change

549 active trials 323 recruiting 29 Phase 3 300 sponsors 82 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-09-16

What changed in the last 30 days showing 42 of 82 changes on 19 trials

2026-09-10
Recruitment suspended
Recruitment suspended: FDA reviewing
NCT06329570 Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment… · NaviFUS Corporation · Phase 1/2
2026-08-26
Recruitment suspended
Recruitment suspended: Drug Supply Issues
NCT04870944 CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors… · Children's Oncology Group · Phase 1/2
2026-08-18
Recruitment suspended
Recruitment suspended: On hold per study team
NCT05607407 Methimazole in Patients With Progressive Glioblastoma · Case Comprehensive Cancer Center · Phase 2
2026-09-16
Primary completion pushed: 2026-10 → 2027-06
Recruitment opened
Completion pushed: 2026-10 → 2027-07
NCT06357377 A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain… · Neonc Technologies, Inc. · Phase 1
2026-09-10
Primary completion pushed: 2027-03 → 2028-03
Sponsor changed: Plus Therapeutics → Cerenome
Recruitment opened
Completion pushed: 2027-03 → 2028-03
NCT07061626 Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in… · Cerenome · Phase 1
2026-09-12
Primary completion pushed: 2026-03-31 → 2026-10-01
Completion pushed: 2026-03-31 → 2026-12-31
NCT04201457 A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG… · Pediatric Brain Tumor Consortium · Phase 1/2
2026-09-01
Primary completion pushed: 2026-10 → 2027-06
Enrollment closed, study ongoing
Completion pushed: 2027-10 → 2028-06
NCT05226494 Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma · NanoPharmaceuticals LLC · Phase 1
2026-08-28
Primary completion pushed: 2025-12 → 2026-12
NCT04794972 A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory… · Sichuan Baili Pharmaceutical Co., Ltd. · Phase 1
2026-09-15
Primary completion pushed: 2026-06-01 → 2026-09-13
Completion pushed: 2026-12-31 → 2027-12-31
NCT06797661 Insights Into the Pathophysiology of Neurovascular Uncoupling in Patients With Brain… · Erasme University Hospital
2026-08-27
Primary completion pushed: 2026-07-01 → 2028-01-01
Completion pushed: 2028-07-01 → 2029-07-01
NCT03048084 Seizure Treatment in Glioma · Leiden University Medical Center · Phase 4
2026-08-27
Primary completion pushed: 2026-01-12 → 2029-01-03
Enrollment increased: 60 → 86 participants
Trial arms changed: 4 → 5
NCT05236036 Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of… · Northwestern University · Phase 1
2026-08-25
Primary completion pushed: 2027-05-11 → 2027-08-20
Completion pushed: 2027-05-11 → 2028-07-20
NCT04214392 Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the… · City of Hope Medical Center · Phase 1
2026-08-18
Primary completion pushed: 2026-03-05 → 2027-07-01
Enrollment closed, study ongoing
Completion pushed: 2027-03-05 → 2027-07-01
NCT06632236 5G-EMERALD: Amivantamab in Malignant Brain Tumours · Institute of Cancer Research, United Kingdom · Phase 1
2026-09-01
Primary completion pushed: 2026-07-31 → 2027-07-31
Completion pushed: 2026-07-31 → 2027-07-31
NCT05489783 Glioma Developmental and HyperActive Ras Tumor (DHART) Board · Memorial Sloan Kettering Cancer Center
2026-08-18
Primary completion pushed: 2026-12 → 2027-12
Completion pushed: 2026-12 → 2027-12
NCT05212272 MRI in High-Grade Glioma Patients Undergoing Chemoradiation · Wake Forest University Health Sciences
2026-08-19
Primary endpoint(s) modified
NCT07767110 Targeted LSAM-Cisplatin Infusion in Gliomas, Evaluation of Response · NanOlogy, LLC · Phase 1/2
2026-08-26
Primary endpoint(s) modified
NCT07781852 Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and… · Lumina Pharmaceuticals Inc · Early Phase 1
2026-08-25
Primary endpoint(s) modified
NCT07778979 Multiparametric Metabolic and Hypoxic PET/MRI Imaging Substudy in Gliomas · University of Alabama at Birmingham · Early Phase 1
2026-09-10
Enrollment reduced: 30 → 22 participants
Primary completion confirmed: July 2026 (last estimated May 2029)
Completion pushed: 2030-05-12 → 2030-08-31
NCT06410248 Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent… · Northwestern University · Phase 1
2026-09-12
Recruitment resumed after suspension
NCT04870944 CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors… · Children's Oncology Group · Phase 1/2

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-09-11 NCT07814872 A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing… Harvard Medical School (HMS and HSDM) new
2026-09-10 NCT07813377 Usefulness of Thromboelastography as a Predictor of Prognosis in Patients Undergoing… Fundacion Clinic per a la Recerca Biomédica new
2026-09-09 NCT07809178 China Treatment Trial for Tumor in Sellar Region With Unruptured Intracranial Aneurysm Cheng sen new
2026-08-27 NCT07789678 Epidemiological Profile of Patients With IDH-Mutant Diffuse Gliomas Diagnosed From 2021… Latin American Cooperative Oncology Group new
2026-08-26 NCT07788677 Tarlatamab Treatment Before and After Surgery in Surgically Resectable Recurrent… Vall d'Hebron Institute of Oncology new Phase 1
2026-08-24 NCT07781852 Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and… Lumina Pharmaceuticals Inc new Early Phase 1
2026-08-17 NCT07767110 Targeted LSAM-Cisplatin Infusion in Gliomas, Evaluation of Response NanOlogy, LLC new Phase 1/2
2026-08-10 NCT07754734 STUPP Regimen With or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT… Dongguan People's Hospital new Phase 2
2026-08-07 NCT07751744 Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in… Jubilant Therapeutics Inc. new Phase 1/2
2026-08-06 NCT07750457 Proton vs. Photon Radiotherapy for Patients With WHO Grade 2-3 Glioma University Hospital, Essen new

Active trials by phase

Early Phase 1
36
Phase 1
130
Phase 1/2
56
Phase 2
88
Phase 2/3
5
Phase 3
24
Phase 4
5
Not charted: 205 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 549

NCT IDTitleSponsorStatusUpdated
Phase 4
NCT03340506 Dabrafenib and/or Trametinib Rollover Study Novartis Pharmaceuticals Recruiting 2026-09-15
NCT03048084 Seizure Treatment in Glioma Leiden University Medical Center Recruiting 2026-08-26
NCT07486713 Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies Rigel Pharmaceuticals Recruiting 2026-08-11
NCT03975829 Pediatric Long-Term Follow-up and Rollover Study Novartis Pharmaceuticals Active, Not Recruiting 2026-08-27
NCT02496988 Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas The First People's Hospital of Changzhou Not Yet Recruiting 2015-07-14
Phase 3
NCT04166409 A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With… National Cancer Institute (NCI) Recruiting 2026-09-11
NCT06809322 Vorasidenib Maintenance for IDH Mutant Astrocytoma European Organisation for Research and Treatment of Cancer - EORTC Recruiting 2026-09-10
NCT07215910 Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for… Alliance for Clinical Trials in Oncology Recruiting 2026-09-02
NCT05303519 SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) Nuvation Bio Inc. Recruiting 2026-08-28
NCT05476939 Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0 Gustave Roussy, Cancer Campus, Grand Paris Recruiting 2026-08-13
NCT06888817 Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic… The Netherlands Cancer Institute Recruiting 2026-07-13
NCT05271240 Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With… Northwell Health Recruiting 2026-06-01
NCT05580562 ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) Jazz Pharmaceuticals Recruiting 2026-04-16
NCT06496971 A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab… NaviFUS Corporation Recruiting 2026-04-09
NCT05331521 A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly… University Hospital Heidelberg Recruiting 2026-02-03
NCT04702581 A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas… Hospices Civils de Lyon Recruiting 2026-01-29
NCT05512403 Evaluation of Diagnostic Performances of 18F-FDOPA PET KInetics Central Hospital, Nancy, France Recruiting 2024-09-19
NCT06330337 Effect of Electroacupuncture Combined With Paclitaxel Clinical Efficacy of Patients With… The Third Affiliated hospital of Zhejiang Chinese Medical University Recruiting 2024-03-26
NCT03871257 A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With… National Cancer Institute (NCI) Active, Not Recruiting 2026-08-13
NCT07712757 Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma Nuvation Bio Inc. Not Yet Recruiting 2026-07-17
NCT07698457 Clinical Benefit of 18F-FET in Glioma. Primo Biotechnology Co., Ltd Not Yet Recruiting 2026-07-13
NCT04576117 A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and… National Cancer Institute (NCI) Active, Not Recruiting 2026-07-02
NCT06780930 Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or… Servier Active, Not Recruiting 2026-06-04
NCT05566795 DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma… Day One Biopharmaceuticals, Inc. Active, Not Recruiting 2026-05-14
NCT02864888 Effect of Antineoplaston Therapy on the QT/QTc Interval In Subjects With Diffuse… Burzynski Research Institute Not Yet Recruiting 2025-09-19
See all 549 active Glioma trials with filters →

Top sponsors by active trials in this area

National Cancer Institute (NCI) (32) · Mayo Clinic (16) · M.D. Anderson Cancer Center (15) · Nationwide Children's Hospital (11) · Beijing Tiantan Hospital (8) · Memorial Sloan Kettering Cancer Center (8) · Tata Memorial Centre (8) · University of California, San Francisco (8) · City of Hope Medical Center (7) · Northwell Health (6)

Get alerts when Glioma trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free